Fiona Okonjo

Fiona Okonjo has a diverse work experience in the field of cancer studies. Fiona began their career in 2010 as a Molecular Biologist and Research Assistant Intern at Oxford Gene Technology. In 2011, they joined the Wellcome Trust Sanger Institute as a Research Assistant, where they were part of a team that screened 639 cancer cell lines with 130 drugs to identify novel biomarkers of drug sensitivity to cancer therapeutics. Her findings were published in the Nature journal. In 2013, they became a PhD Student at King's College London, where they developed breast cancer cell lines harbouring genetic knockout of the histone demethylase enzyme, using CRISPR. Fiona also supervised two Master's students research projects, which were both awarded distinctions. In 2018, they joined the University of Oxford as a Postdoctoral Researcher and Researcher Strategy Consultant-Health and Life sciences. During this time, they successfully accomplished Project Management lead roles for 3 projects and identified an opportunity to improve knowledge gap in understanding the genetic determinants of a histone mark loss. Lastly, they joined NanoSyrinx in 2021 as a Staff Scientist.

Fiona Okonjo has a long education history. Fiona began their studies in 2005 at the University of Liverpool, where they obtained a BSc (Hons) in Genetics. Fiona then went on to pursue an MSc in Molecular Medicine at Imperial College London from 2008 to 2009. Finally, they completed a 1 year MRes and 3 year PhD in Cancer Studies at King's College London between 2013 and 2018.